Back to search results

PGx Medication Safety Reviews for People with Intellectual and Developmental Disabilities

This study is looking at how useful it is to review medications and use pharmacogenetic (PGx) testing for people with intellectual and developmental disabilities (IDD). PGx testing uses a cheek swab to see how your genes might affect how you respond to certain medicines. The study will involve a pharmacist reviewing all medications for participants. The goal is to see if these steps can help improve how medications are managed and overall health. You can join if you are at least 21 years old, have IDD, and live in a CP Unlimited facility in NY state. The study aims to enroll 700 participants. The study is currently unclear on its recruitment status.

Study design
This is an observational study, meaning researchers will observe and collect information without giving new treatments. It plans to include 700 participants.
What's involved
You would provide a cheek swab for PGx testing and have a pharmacist review your medications. The study will last for two years.
Compensation
Not stated in the trial record.
Follow-up
The study will measure outcomes for two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07092852

PGx Medication Safety Reviews of Persons With IDD

Not Yet Recruiting
Not specifiedAges 21+Observational
GalenusRx, Inc.
~700 participants
Updated 2025-07-30 on ClinicalTrials.gov
What's tested:Cheek swab for PGx testingMedication safety review

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Measure the Feasibility of PGx Testing in IDD Population
Measured over Two years
+1 more outcome measured

Conditions

Intellectual Disability, Mild
Intellectual Disability, Mild to Moderate
Developmental Disability

Explore related trials

Developmental DisorderIntellectual Disability

Where it's being run

2 sites across 2 states
Florida1
New York1

Study leadership

  • Veronique Michaud, BPharm, MSc, PhD · PRINCIPAL_INVESTIGATOR · GalenusRx, Inc.
  • Ira Salom, MD · PRINCIPAL_INVESTIGATOR · CP Unlimited

Who to contact

Ira L Salom, MD, MSc(Med), FACP, CPE
[email protected]
718-665-7565
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Beneficiary with IDD
Reside in a CP Unlimited facility, NY state
At least 21 years of age

Exclusion

Pregnant
Medical or physical abnormality that prevents cheek swab collection

What this trial measures

  • Measure the Feasibility of PGx Testing in IDD PopulationTwo years

    Measure feasibility of a PGx testing program calculating the number of pharmacogenetic tests / medication safety reviews completed.

  • Measure the Acceptability of Implementing a PGx ProgramTwo years

    Measure the acceptability of implementing a PGx program by examining the recommendations accepted and transferred to a dispensing pharmacy.